Supplemental Tables
Supplemental Table 1 All summary statistics are absolute counts (%) for categorical variables and median (inter-quartile range = IQR) for continuous data. n refers to the number of patients with non-missing data for the corresponding variable. # MRC denotes modified British Medical Research Council criteria. MRC1 indicates a GCS of 15 with no neurologic signs (baseline), MRC2 a score of 11 to 14 (or 15 with focal neurologic signs), and MRC3 a score of 10 or less. *Diagnostic categories were assigned according to the consensus case definition (Marais et al.; The Lancet Infectious diseases. 2010; 10(11): 803-12). All summary statistics are absolute counts (%) for categorical variables and median [inter-quartile range] for continuous data. n refers to the number of patients with non-missing data for the corresponding variable. *Negative means lipid measurement under the detection limit. Positive means lipid measurement above the detection limit.** Note that p value <0.05 All summary statistics are absolute counts (%) for categorical variables and median (inter-quartile range = IQR) for continuous data, and mean and 95% CI for lipid mediator reduction measurement. n refers to the number of patients with non-missing data for the corresponding variable. ** Note that p value <0.05 All summary statistics are absolute counts (%) for categorical variables and median (inter-quartile range = IQR) for continuous data, and mean and 95% CI for lipid mediator reduction measurement. n refers to the number of patients with non-missing data for the corresponding variable. ** Note that p.value <0.05
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Supplemental Figure 1 : Increased free fatty acid concentrations and ALOX15 products with increasing disease severity. CSF were collected from patients with TBM before the start of treatment and products were extracted, identified and quantified using lipid mediator profiling. (A) free fatty acid concentrations. (B-E) summation of (B) ALOX15 products -17-HDHA, 17-HDPA, 15-HEPE, 15-HETE (C) ALOX12 products -14-HDHA, 14-HDPA, 12-HEPE, 12-HETE (D) ALOX5 products -7-HDHA, 7-HDPA, 5-HEPE, 5-HETE (E) COX products -13-HDHA, 13-HDPA. Statistical differences were determined using one-way ANOVA followed by test for linear trend. Results are mean ± SEM. n = 44 for MRC 1; n = 47 for MRC2 and n = 12 for MRC3. 
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